Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

INDO US BIO-TECH LTD.

NSE : INDOUSBSE : 541304ISIN CODE : INE250Z01010Industry : AgricultureHouse : Private

BSE153.400 (0 %)

PREV CLOSE ( ) 153.40

OPEN PRICE ( ) 153.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 301

TODAY'S LOW / HIGH ( )153.00 153.40

52 WK LOW / HIGH ( )147.25 386

NSE157.475.25 (+3.45 %)

PREV CLOSE( ) 152.22

OPEN PRICE ( ) 158.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 2335

TODAY'S LOW / HIGH( ) 155.00 158.90

52 WK LOW / HIGH ( )145 388.4

Select year

Particulars

Mar 2022

Mar 2021

Mar 2020

Operational & Financial Ratios

Earnings Per Share (Rs)

5.52

8.07

4.18

CEPS(Rs)

3.01

3.54

1.89

DPS(Rs)

0.00

Book NAV/Share(Rs)

42.01

35.15

27.05

Tax Rate(%)

4.67

-24.71

11.49

Margin Ratios

Core EBITDA Margin(%)

13.54

13.28

9.97

EBIT Margin(%)

13.01

12.74

9.43

Pre Tax Margin(%)

10.61

9.80

7.20

PAT Margin (%)

10.11

12.22

6.37

Cash Profit Margin (%)

11.01

12.86

6.91

Performance Ratios

ROA(%)

10.27

12.54

7.31

ROE(%)

16.92

25.96

15.44

ROCE(%)

15.46

17.65

15.00

Asset Turnover(x)

1.01

1.03

1.15

Sales/Fixed Asset(x)

12.64

21.23

28.24

Working Capital/Sales(x)

1.45

2.00

2.62

Efficiency Ratios

Fixed Capital/Sales(x)

0.08

0.05

0.04

Receivable days

164.98

207.85

192.56

Inventory Days

128.46

95.67

83.98

Payable days

-235.19

0.00

667.11

Valuation Parameters

PER(x)

12.22

3.36

10.24

PCE(x)

11.23

3.83

11.34

Price/Book(x)

1.61

0.93

1.90

Yield(%)

0.00

EV/Net Sales(x)

1.49

0.78

0.99

EV/Core EBITDA(x)

10.73

5.81

9.96

EV/EBIT(x)

11.46

6.10

10.55

EV/CE(x)

1.35

0.72

1.14

M Cap / Sales

1.24

0.49

0.78

Growth Ratio

Net Sales Growth(%)

24.80

0.88

0.00

Core EBITDA Growth(%)

29.62

35.18

0.00

EBIT Growth(%)

27.47

36.33

0.00

PAT Growth(%)

3.34

93.30

0.00

EPS Growth(%)

-31.59

93.30

0.00

Financial Stability Ratios

Total Debt/Equity(x)

0.33

0.54

0.52

Current Ratio(x)

3.81

2.11

1.91

Quick Ratio(x)

1.91

1.45

1.36

Interest Cover(x)

5.42

4.33

4.24

Total Debt/Mcap(x)

0.21

0.59

0.28